Javier García-Ferreyra, Roly Hilario, Daniel Luna, Lucy Villegas, Rocío Romero, Patricia Zavala, Julio Dueñas-Chacón
{"title":"使用INVOcell装置的体内培养系统显示出与ICSI程序中使用体内培养系统获得的相似的妊娠和着床率。","authors":"Javier García-Ferreyra, Roly Hilario, Daniel Luna, Lucy Villegas, Rocío Romero, Patricia Zavala, Julio Dueñas-Chacón","doi":"10.4137/CMRH.S25494","DOIUrl":null,"url":null,"abstract":"<p><strong>Capsule: </strong>Clinical outcomes using INVOcell device with ICSI.</p><p><strong>Objective: </strong>Intravaginal culture of oocytes (INVO) procedure is an intravaginal culture system that utilizes the INVOcell device in which the fertilization and embryo culture occur. In this procedure, the vaginal cavity serves as an incubator for oocyte fertilization and early embryonic development. The objective of this study was to evaluate the clinical outcomes of this intravaginal culture system in intracytoplasmic sperm injection (ICSI).</p><p><strong>Methods: </strong>A total of 24 cycles INVO-ICSI (study group) and 74 cycles of ICSI (control group) were included in the study. The cleaved oocytes at day 3/total injected oocytes, embryo quality, pregnancy rate (PR), implantation rate (IR), and miscarriage rate (MR) were compared between both groups.</p><p><strong>Results: </strong>At day 3, there was no difference in the cleaved oocyte rate (78.7 and 76.1%) and embryo quality (77 and 86.8%) for the study and control groups, respectively. In the study group, more embryos were significantly transferred compared to the control group (2.63 ± 0.58 versus 1.93 ± 0.25; P < 0.05). PRs, IRs, and MRs were similar for the study group compared with the control group (PR: 54.2% versus 58.1%; IR: 31.7% versus 33.6%; MR: 7.7% versus 20.9%).</p><p><strong>Conclusions: </strong>Good PR and IR can be obtained using the INVOcell device, and the INVO-ICSI procedure can be considered as an alternative option to infertile patients.</p>","PeriodicalId":44130,"journal":{"name":"Clinical Medicine Insights-Reproductive Health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/CMRH.S25494","citationCount":"6","resultStr":"{\"title\":\"In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures.\",\"authors\":\"Javier García-Ferreyra, Roly Hilario, Daniel Luna, Lucy Villegas, Rocío Romero, Patricia Zavala, Julio Dueñas-Chacón\",\"doi\":\"10.4137/CMRH.S25494\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Capsule: </strong>Clinical outcomes using INVOcell device with ICSI.</p><p><strong>Objective: </strong>Intravaginal culture of oocytes (INVO) procedure is an intravaginal culture system that utilizes the INVOcell device in which the fertilization and embryo culture occur. In this procedure, the vaginal cavity serves as an incubator for oocyte fertilization and early embryonic development. The objective of this study was to evaluate the clinical outcomes of this intravaginal culture system in intracytoplasmic sperm injection (ICSI).</p><p><strong>Methods: </strong>A total of 24 cycles INVO-ICSI (study group) and 74 cycles of ICSI (control group) were included in the study. The cleaved oocytes at day 3/total injected oocytes, embryo quality, pregnancy rate (PR), implantation rate (IR), and miscarriage rate (MR) were compared between both groups.</p><p><strong>Results: </strong>At day 3, there was no difference in the cleaved oocyte rate (78.7 and 76.1%) and embryo quality (77 and 86.8%) for the study and control groups, respectively. In the study group, more embryos were significantly transferred compared to the control group (2.63 ± 0.58 versus 1.93 ± 0.25; P < 0.05). PRs, IRs, and MRs were similar for the study group compared with the control group (PR: 54.2% versus 58.1%; IR: 31.7% versus 33.6%; MR: 7.7% versus 20.9%).</p><p><strong>Conclusions: </strong>Good PR and IR can be obtained using the INVOcell device, and the INVO-ICSI procedure can be considered as an alternative option to infertile patients.</p>\",\"PeriodicalId\":44130,\"journal\":{\"name\":\"Clinical Medicine Insights-Reproductive Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4137/CMRH.S25494\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Medicine Insights-Reproductive Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4137/CMRH.S25494\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Reproductive Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4137/CMRH.S25494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6
摘要
胶囊:使用INVOcell装置进行ICSI的临床结果。目的:卵母细胞阴道内培养(INVO)是一种利用INVOcell装置进行受精和胚胎培养的阴道内培养系统。在这个过程中，阴道作为卵母细胞受精和早期胚胎发育的孵化器。本研究的目的是评估这种阴道内培养系统在卵胞浆内单精子注射(ICSI)中的临床效果。方法:共纳入24个周期的INVO-ICSI(研究组)和74个周期的ICSI(对照组)。比较两组第3天卵裂卵母细胞/总注射卵母细胞数、胚胎质量、妊娠率(PR)、着床率(IR)和流产率(MR)。结果:第3天，实验组和对照组的卵裂卵率(78.7和76.1%)和胚胎质量(77和86.8%)差异无统计学意义。研究组的胚胎移植数明显多于对照组(2.63±0.58 vs 1.93±0.25);P < 0.05)。与对照组相比，研究组的PR、IRs和MRs相似(PR: 54.2%对58.1%;IR: 31.7% vs 33.6%;MR: 7.7%对20.9%)。结论:使用INVOcell装置可获得良好的PR和IR, INVO-ICSI手术可作为不孕症患者的替代选择。
In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures.
Capsule: Clinical outcomes using INVOcell device with ICSI.
Objective: Intravaginal culture of oocytes (INVO) procedure is an intravaginal culture system that utilizes the INVOcell device in which the fertilization and embryo culture occur. In this procedure, the vaginal cavity serves as an incubator for oocyte fertilization and early embryonic development. The objective of this study was to evaluate the clinical outcomes of this intravaginal culture system in intracytoplasmic sperm injection (ICSI).
Methods: A total of 24 cycles INVO-ICSI (study group) and 74 cycles of ICSI (control group) were included in the study. The cleaved oocytes at day 3/total injected oocytes, embryo quality, pregnancy rate (PR), implantation rate (IR), and miscarriage rate (MR) were compared between both groups.
Results: At day 3, there was no difference in the cleaved oocyte rate (78.7 and 76.1%) and embryo quality (77 and 86.8%) for the study and control groups, respectively. In the study group, more embryos were significantly transferred compared to the control group (2.63 ± 0.58 versus 1.93 ± 0.25; P < 0.05). PRs, IRs, and MRs were similar for the study group compared with the control group (PR: 54.2% versus 58.1%; IR: 31.7% versus 33.6%; MR: 7.7% versus 20.9%).
Conclusions: Good PR and IR can be obtained using the INVOcell device, and the INVO-ICSI procedure can be considered as an alternative option to infertile patients.
期刊介绍：
Clinical Medicine Insights: Reproductive Health is a peer reviewed; open access journal, which covers all aspects of Reproduction: Gynecology, Obstetrics, and Infertility, spanning both male and female issues, from the physical to the psychological and the social, including: sex, contraception, pregnancy, childbirth, and related topics such as social and emotional impacts. It welcomes original research and review articles from across the health sciences. Clinical subjects include fertility and sterility, infertility and assisted reproduction, IVF, fertility preservation despite gonadotoxic chemo- and/or radiotherapy, pregnancy problems, PPD, infections and disease, surgery, diagnosis, menopause, HRT, pelvic floor problems, reproductive cancers and environmental impacts on reproduction, although this list is by no means exhaustive Subjects covered include, but are not limited to: • fertility and sterility, • infertility and ART, • ART/IVF, • fertility preservation despite gonadotoxic chemo- and/or radiotherapy, • pregnancy problems, • Postpartum depression • Infections and disease, • Gyn/Ob surgery, • diagnosis, • Contraception • Premenstrual tension • Gynecologic Oncology • reproductive cancers • environmental impacts on reproduction, • Obstetrics/Gynaecology • Women''s Health • menopause, • HRT, • pelvic floor problems, • Paediatric and adolescent gynaecology • PID
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
